Bladder Cancer Coverage from Every Angle

ASTRO 2020: Outcomes With Radiotherapy in Men and Women With Urothelial Bladder Cancer

By: Julia Fiederlein
Posted: Wednesday, November 4, 2020

Alexander A. Harris, MD, of Loyola University, Chicago, and colleagues conducted a study to examine the differences in the utilization of curative radiation therapy and the impact on overall survival among men and women with muscle-invasive urothelial bladder cancer. The results of the analysis were presented during the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 4146).

The researchers focused on data from the National Cancer Database on 5,221 patients with cT2–T4 N0 M0 urothelial carcinoma of the bladder who received local excision and radiation therapy. Of this study population, 30% were female. Patients were stratified by the type of radiation therapy delivered: palliative radiation (44.9%), definitive radiation (25%), and definitive chemoradiation (30.1%). Follow-up data were provided for a median of 17.9 months.

Based on a univariate analysis, geographic region, age, race, population density, distance traveled for treatment, Charlson/Deyo Comorbidity Index, tumor grade, and T stage seemed to significantly differ between the sexes. Results of the multivariate analysis revealed significant differences in geographic region, age, race, Charlson/Deyo Comorbidity Index, T stage, and type of radiation treatment delivered between men and women.

More women were treated with palliative radiation than men (52.8% vs. 41.5%, respectively). The median overall survival was 19.4 months; the 2-year overall survival rate was 43.8%. The 2-year overall survival rate was 40.2% in women and 45.2% in men (P = .02), based on the results of the univariate analysis. Geographic region, age, insurance status, income, education, population density, Charlson/Deyo Comorbidity Index, T stage, and type of radiation treatment delivered also appeared to influence overall survival. Based on the multivariate analysis, overall survival seemed to be influenced by geographic region, age, Charlson/Deyo Comorbidity Index, T stage, and type of radiation treatment delivered; however, it did not seem to be significantly impacted by the sex of the patient.

Disclosure: For full disclosures of study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.